2014

Reportlinker Adds Product Profiles: Autism Spectrum Disorders -Underserved market eagerly anticipates pipeline trial data

NEW YORK, June 27, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Product Profiles: Autism Spectrum Disorders -Underserved market eagerly anticipates pipeline trial data

http://www.reportlinker.com/p0564411/Product-Profiles-Autism-Spectrum-Disorders--Underserved-market-eagerly-anticipates-pipeline-trial-data.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Introduction

Over the past 6 years, three major events have impacted the autism spectrum disorders market. In 2006, Risperdal became the first drug to receive approval from the US FDA for the symptomatic treatment of irritability in children and adolescents with ASDs. Later, in 2009, the FDA approval Abilify for the same indication. In 2008, generic risperidone launched following Risperdal's US patent expiry.

Features and benefits

* Overview of marketed and pipeline drugs in clinical development for autism spectrum disorders.

* Analysis of the market positioning of each product approved for the treatment of autism spectrum disorders.

* Assessment of the strengths, weaknesses, opportunities and threats for marketed and late-stage pipeline candidates.

* Summary of the clinical and commercial attractiveness for each of the marketed products.

* Insight from key opinion leaders on marketed and pipeline products.

Highlights

Risperdal and Abilify are the only two products approved for the treatment of autism spectrum disorders (ASDs). Both of these atypical antipsychotics are indicated for the management of irritability symptoms associated with ASDs in the US. Due to the failure of these drugs to address the core symptoms of ASDs, many other drugs are used off-label.

Abilify is the most recent entrant to the ASDs market, having received US Food and Drug Administration (FDA) approval in November 2009. The drug's partial agonism of dopamine receptors unique mechanism of action is considered a key differentiating factor, producing a superior side-effect profile compared to other atypical antipsychotics.

To date, none of the four late-stage pipeline candidates for autism spectrum disorders has publically presented the late-stage Phase II or III trial data necessary for the clinical assessment of these compounds.

Your key questions answered

* What are the key differentiating features of approved therapies for the treatment of autism spectrum disorders?

* How do key opinion leaders perceive available treatments for autism spectrum disorders?

* What opportunities are there for existing players in the autism spectrum disorders market to increase their market share?

* What is the development status of current pipeline candidates development status?

* What clinical trial design are current pipeline canddiates following? What do pipeline candidates need to demonstrate in order to be successful?

Executive Summary

Strategic scoping and focus

Datamonitor key findings

Related reports

OVERVIEW

Catalyst

Summary

MARKET DEFINITION AND OVERVIEW

Market definition

Product overview

MARKETED PRODUCT PROFILES

Abilify (aripiprazole; Bristol-Myers Squibb/Otsuka Pharmaceuticals)

Drug profile

Development overview

SWOT analysis

Product positioning

Clinical and commercial attractiveness

Risperdal (risperidone; Johnson & Johnson)

Drug profile

Development overview

SWOT analysis

Product positioning

Clinical and commercial attractiveness

PIPELINE PRODUCT PROFILES

CM-AT (Curemark)

Drug profile

Development overview

SWOT analysis

Other drugs in clinical development for autism spectrum disorders

STX-209 (arbaclofen; Seaside Therapeutics)

UCB-MNC (umbilical cord blood mononuclear stem cells; Beike Biotech)

CYP-2001 (carbetocin; Cypress Bioscience)

BIBLIOGRAPHY

Journal papers

Websites

Datamonitor reports

APPENDIX

Contributing experts

Conferences attended

Report methodology

To order this report:

Pathology Industry: Product Profiles: Autism Spectrum Disorders -Underserved market eagerly anticipates pipeline trial data

Pathology Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS
http://www.reportlinker.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.